Medicine guide

ZEFFIX

As listed in the register: ZEFFIX 5 mg/ml, solution buvable

5 mg · solution buvable

  • Prescription only
Active substance
Lamivudine
Made by
GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Lamivudine). It describes the substance, not this exact product.

Lamivudine is an antiviral agent with activity against HBV [see Microbiology ( 12.4 )].

Half-life13–19 h
Mostly cleared after≈ 3 daysfive half-lives — our arithmetic
How the body breaks it down

Lamivudine is not significantly metabolized by cytochrome P450 enzymes.

How it leaves the body

The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion.

With food

Effects of Food on Oral Absorption: Lamivudine tablets (HBV) may be administered with or without food.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-29

Safety of the active substance

From the US prescribing label for the same active substance (Lamivudine). It describes the substance, not this exact product.

Serious warning

WARNING: EXACERBATIONS OF HEPATITIS B and RISK OF HIV-1 RESISTANCE IF LAMIVUDINE TABLETS (HBV) IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1 INFECTION Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy (including lamivudine tablets (HBV).

Must not be used by
  • Lamivudine tablets (HBV) are contraindicated in patients with a previous hypersensitivity reaction to lamivudine.
  • Lamivudine tablets (HBV) is contraindicated in patients with previous hypersensitivity reaction to lamivudine.
Most common side effects

The most common reported adverse reactions in those receiving lamivudine tablets (HBV) (incidence greater than or equal to 10% and reported at a rate greater than placebo) were ear, nose, and throat infections; sore throat; and diarrhea.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

Details

Made byGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
Active substanceLamivudine
Strength5 mg
Formsolution buvable
Routeorale
Dispensing (as stated by the register)prescription réservée aux spécialistes et services HEPATO/GASTRO-ENTEROLOGIE · prescription réservée aux spécialistes et services MEDECINE INTERNE · prescription réservée aux spécialistes et services INFECTIOLOGIE · prescription initiale semestrielle réservée à certains spécialistes · liste I · renouvellement non restreint
MarketedYes, according to the register
Authorisation procedureProcédure centralisée
EU numberEU/1/99/114
Name in the registerZEFFIX 5 mg/ml, solution buvable
Packs1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 240 ml avec adaptateur(s) pour flacon polyéthylène
CIS68427877
CIP133400935196941

Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician

Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).

Other strengths and forms

2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

  • solution buvable1 products
    • 5 mg
  • comprimé pelliculé1 products

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.